Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Eli Lilly to Acquire Drug Developer Ventyx for $1.2 Billion, Expanding in Autoimmune Field

Eli Lilly to Acquire Drug Developer Ventyx for $1.2 Billion, Expanding in Autoimmune Field

格隆汇格隆汇2026/01/08 02:13
Show original
By:格隆汇
Gelonghui Jan 8th|Eli Lilly will acquire autoimmune drug developer Ventyx Biosciences at a price of $14 per share, with the deal valued at $1.2 billion. Ventyx is developing multiple therapeutic drugs, including oral therapies for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, as well as medications for immune-related diseases, cardiometabolic diseases, and neurodegenerative diseases. In addition, the company is conducting a mid-stage trial for a drug targeting obesity-related cardiovascular diseases, which could potentially complement Eli Lilly's metabolic and immunology franchises. The transaction is expected to be completed in the first half of this year.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
© 2025 Bitget